Selexis SA announced that under the terms of an earlier commercial license agreement, Symphogen A/S has opened two investigational new drug applications (INDs) for clinical programs utilizing Selexis’ SGE® (Selexis Genetic Elements).
The Symphogen antibody candidates, Sym022 and Sym023, are for the treatment of patients with locally advanced/unresectable or metastatic solid tumors or lymphomas that are refractory to available therapy or for which no standard therapy is available.
Selexis’ proprietary SUREtechnology Platform facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein, including biosimilars, and provides seamless integration of the biologics development continuum, spanning discovery to commercialization.
In December 2014, Selexis and Symphogen A/S entered into a commercial license agreement and signed the continuation of their R&D license agreement. Symphogen has licensed the rights to the Selexis SUREtechnology Platform and SURE CHO-M Cell Line™ for the development of recombinant mAb mixtures for the treatment of various cancers and infectious diseases. In June 2016, Symphogen announced its clinical candidate Sym015 had advanced into clinical development using Selexis SGE® (Selexis Genetic Elements).
Selexis SA (Plan-les-Ouates, Switzerland) is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines.
Symphogen A/S (Ballerup, Denmark) is a clinical late-stage oncology-focused company with a novel and differentiated monoclonal antibody product pipeline with significant commercial opportunities. Symphogen has pioneered the field of antibody mixtures for therapeutic use in oncology and other significant diseases.